Progression of HIV: Follow-up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-1985

AIDS

Volumn 10, Issue 4, 1996, Pages 419-430

  Brettle, Raymond P ^a   McNeil, Alexander J ^b   Burns, Sheila ^a   Gore, Sheila M ^c   Bird, A Graham ^d   Yap, Peng Lee ^e   MacCallum, Linda ^a   Leen, Clifford S L ^a   Richardson, Alison M ^a  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e Regional Blood Transfusion Service   (United Kingdom)

Author keywords

Age; B8; CD4 counts; DR3; Gender; HLA A1; HLA B27; Injecting drug use; Progression; Weibull incubation period

Indexed keywords

CD4 ANTIGEN; HLA ANTIGEN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DISEASE COURSE; DRUG USE; FEMALE; GENDER; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCUBATION TIME; INTRAVENOUS DRUG ABUSE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; SURVIVAL RATE; SURVIVAL TIME;

EID: 0029917584     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199604000-00011     Document Type: Article

References (70)

1. Selwyn PA, Alcabes P, Hartel D, et al.: Clinical manifestations and predictors of disease progression in drug users with HIV infection. N Engl J Med 1992, 327:1697-1703.
2. Gatell JM, Podzamczer D, Clotet B, Estany C, Miro JM and Barcelona AIDS Study Group: Natural history of HIV infection in European drug users. AIDS 1989, 3:404.
3. Galli M, Lazzarin A, Saracco A, et al.: Clinical and immunological aspects of HIV infection in drug addicts. Clin Immunol Immunopathol 1989, 50:S166-S176.
4. Fernandez-Cruz E, Desco M, Montes MG, Longo N, Gonzalez B, Zabay JM: Immunological and serological markers predictive of progression to AIDS in a cohort of HIV infected drug users. AIDS 1990, 4:987-994.
5. The Italian Seroconversion Study: Disease progression and early predictors of AIDS in HIV seroconverted injecting drug users. AIDS 1992, 6:421-426.
6. Chaisson RE, Keruly JC, Moore RD: Race, sex, drug use and progression of HIV disease. N Engl J Med 1995, 333:751-756.
7. Marmion BP, Tomkin RW: Control of hepatitis in dialysis units. Br Med Bull 1972, 28:169-178.
8. Burns SM, Brettle RP, Gore SM, Peutherer JF, Robertson JR: Epidemiology of HIV associated with injection drug use in Edinburgh. J Infect (in press).
9. Ronald PJM, Robertson JR, Elton RA: Continued drug use and other cofactors for progression to AIDS among injecting drug users. AIDS 1994, 8:339-343.
10. Robertson JR, Bucknall ABV, Welsby PD, et al.: An epidemic of AIDS-related virus (HTLV-III/LAV) infection amongst intravenous drug abusers in a Scottish general practice. BMJ 1986, 292:527-530.
11. Peutherer JF, Edmond E, Simmonds P, Dickson JD, Bath GE: HTLV-III antibody in Edinburgh drug addicts. Lancet 1985, ii:1129-1130.
12. Robertson JR, Bucknall ABV, Wiggins P: Regional variations in HIV antibody seropositivity in British intravenous drug users. Lancet 1986, i:1435-1436.
13. Brettle RP, Bisset K, Burns S, et al.: Human immunodeficiency virus and drug misuse - the Edinburgh experience. BMJ 1987, 295:421-424.
14. Bisset C, Jones G, Davidson J, et al.: Mobility of injection drug users and transmission of HIV. Lancet 1989, ii:44.
15. Brettle RP, Gore SM, McNeil A: Outpatient medical care of injection drug use related HIV. Int J STD AIDS 1992, 3:96-100.
16. Brettle RP, Willocks L, Hamilton BA, et al.: Out patient medical care in Edinburgh for IDU related HIV. AIDS Care 1994, 6:49-58.
17. Brettle RP, McNeil AJ, Gore SM, Bird AG, Leen CSL, Richardson A: Analysis of enrolment, progression, survival, mortality and descriptive covariates in the Edinburgh City Hospital Cohort. Q J Med 1995, 88:479-491.
18. Terasaki PI (Ed): Histocompatibility Testing 1980. Los Angeles: UCLA Press; 1980.
19. Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 36:1S-15S.
20. Centers for Disease Control: Classification system for human T-lymphotropic virus type III/lymphadenopthy-associated virus infections. MMWR 1986, 35:334-339.
21. Cox DR, Oakes D: Analysis of Survival Data. London: Chapman and Hall; 1984:177.
22. Aitkin M, Clayton D: The fitting of exponential, Weibull and extreme value distributions to complex censored survival data using GLIM. Appl Stat 1980, 29:156-163.
23. McNeil AJ: Statistical Methods in AIDS Progression Studies with an Analysis of The Edinburgh City Hospital Cohort (PhD Thesis). Cambridge: Cambridge University; 1993.
24. Lindley DV, Smith AFM: Bayes estimates for the linear model. J R Stat Soc (B) 1971, 34:1-41.
25. McNeil AJ, Gore SM: Statistical analysis of zidovudine effect on CD4 counts in HIV disease. Stat Med 1996, 15:75-92.
26. McNeil AJ, Yap PLY, Gore SM, et al.: Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. Q J Med (in press).
27. Bird AG, Gore SM, Joliffe DW, Burns SM: Anonymous HIV surveillance in Saughton Prison, Edinburgh. AIDS 1992, 6:725-733.
28. Ouattra SA, Meite M, Aron Y, et al.: Increase of the prevalence of hepatitis B virus surface antigen related to immunodeficiency inherent in AIDS. J Acquir Immune Defic Syndr 1990, 3:282-286.
29. Bodsworth NJ, Cooper DA, Donovan B: The influence of HIV type 1 infection on the development of hepatitis B virus carrier state. J Infect Dis 1991, 163:1138-1140.
30. Eskild A, Magnus P, Peterson G, et al.: Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS 1992, 6:571-574.
31. Scharschmidt BF, Held MJ, Hollander HH, et al.: Hepatitis B in patient with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992, 117:837-838.
32. Veuglers PJ, Page KA, Tindall B, et al.: Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol 1994, 140:747-758.
33. Lee CA, Philips AN, Elford J, Janossy G, Griffiths P, Kernoff P: Progression of HIV disease in a haemophiliac cohort followed for 11 years and the effect of treatment. BMJ 1991, 303:1093-1096.
34. Fernández-Cruz E, Desco M, Montes MG, Longo N, Gonzalez B, Zabay JM: Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users. AIDS 1990, 4:987-994.
35. Blaxhult A, Granath F, Lidman K, Giesecke J: The influence of age on the latency period to AIDS in people infected by HIV through blood transfusion. AIDS 1990, 4:125-129.
36. Medley GF, Anderson RM, Cox DR, Billard L: Incubation period of AIDS in patients infected via blood transfusion. Nature 1987, 328:719-723.
37. Goedert JJ, Kessler CM, Aledort LM, et al.: A prospective study of HIV type 1 infection and the development of AIDS in subjects with haemophilia. N Engl J Med 1989, 321:1141-1148.
38. Schinaia N, Ghirardini A, Chiarotti, F, Gringeri A, Mannucci PM and the Italian Group: Progression to AIDS among Italian HIV-seropositive hemophiliacs. AIDS 1991, 5:385-391.
39. Moss AR, Bacchetti P: Natural history of HIV infection. AIDS 1989, 3:55-61.
40. Rutherford GW, Lifson AR, Hessol NA, et al.: Course of HIV-1 infection in a cohort of homosexual and bisexual men: an 11 year follow up study. BMJ 1990, 301:1183-1188.
41. Hendriks JCM, Medley GF, van Griensven GJP, Coutinho RA, Heisterkamp SH, van Druten HAM: The treatment free incubation period of AIDS in a cohort of homosexual men. AIDS 1993, 7:231-239.
42. Philips AN, Elford J, Sabin C, Bofil M, Janossy G, Lee CA: Immunodeficiency and the risk of death in HIV infection. J Am Med Assoc 1992, 268:2662-2666.
43. Multicohort Analysis Project Workshop: Extending public health surveillance of HIV infection: information from a five cohort workshop. Stat Med 1993, 12:2065-2085.
44. Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-881.
45. Stoneburner RL, Des Jarlais DC, Benezra D, et al.: A larger spectrum of severe HIV-1 related disease in intravenous drug users in New York City. Science 1989, 242:916-918.
46. Zaccarelli M, Gattari P, Rezza G, et al.: Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS 1994, 8:345-350.
47. van Haastrecht HJA, van den Hock AR, Coutinho RA: High mortality among HIV-infected injecting drug users without AIDS diagnosis: implications for HIV infection epidemic modellers? AIDS 1994, 8:363-366.
48. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):1-19.
49. Galai N, Vlahov D, Margolick JB, Chen K, Graham MH, Munoz A: Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J Acquir Immune Defic Syndr 1995, 8:66-74.
50. Selwyn PA, Alcabes P, Hartel D, et al.: Clinical manifestations and predictors of disease progression in drug users with HIV infection. N Engl J Med 1992, 327:1697-1703.
51. Steel CM, Ludlam CA, Beatson D, et al.: HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988, i:1185-1188.
52. Kaslow RA, Duquesnoy R, VanRaden M, et al.: A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. Lancet 1990, 335:927-930.
53. Kaplan C, Muller JY, Doinel C, et al.: HLA-associated susceptibility to acquired immune deficiency syndrome in HIV-1-seropositive subjects. Hum Hered 1990, 40:290-298.
54. Scorza Smeraldi R, Lazzarin A, Moroni M, Fabio G, Eisera NB, Zanussi M: HLA-associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human immunodeficiency virus infection. Lancet 1986, ii: 1187-1189.
55. Itescu S, Mathurwagh U, Skovron ML, et al.: HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr 1992, 5:37-45.
56. Sahmoud T, Laurian Y, Gazengel C, Sultan Y, Gautreau C, Costagliola D: Progression to AIDS in French haemophiliacs: association with HLA-B35. AIDS 1993, 7:497-500.
57. Mann DL, Murray C, Yarchoan R, Blattner WA, Goedert JJ: HLA antigen frequencies in HIV-1-seropositive disease-free individuals and patients with AIDS. J Acquir Immune Defic Syndr 1988, 1:13-17.
58. Pollack MS, Safai B, Dupont B: HLA-DR5 and DR-2 are susceptibility factors for acquired immunodeficiency syndrome with Kaposi's sarcoma in different ethnic sub-populations. Dis Markers 1983, 1:135-139.
59. Munoz A, Kirby AJ, He YD, et al.: Long term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr 1995, 8:496-505.
60. Phillips AN, Lee CA, Elford J, et al.: Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991, 337:389-392.
61. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W: The characterization of non-progressors: long term HIV-1 infection with stable CD4+T-cell levels. AIDS 1993, 7:1159-1166.
62. Easterbrook PJ: Non-progression in HIV infection. AIDS 1994, 8:1179-1182.
63. Phillips AN, Sabin CA, Mocroft A: Active drug injecting and progression of HIV infection. AIDS 1994, 8:385-386.
64. Sabin CA, Phillips AN, Lee CA, Janossy GJ, Emery V, Griffiths PD: The effect of CMV infection on progression of HIV disease in a cohort of haemophiliac men followed for up to 13 years. Epidemiol Infect 1995, 1154:361-372.
65. Sabin CA, Telfer P, Phillips AN, Elford J, Dusheiko G, Lee CA: Long term survival in HIV infection: the effect of co-infection with hepatitis C on the morbidity and mortality in a cohort of haemophiliac men. Fifth European Conference on Clinical Aspects and Treatment of HIV infection. Copenhagen, September 1995 [abstract 12].
66. Luo K, Law M, Kaldor JM, McDonald AM, Cooper DA: The role of initial AIDS-defining illness in survival following AIDS. AIDS 1995, 9:57-63.
67. Lundgren JD, Pedersen C, Clumeck N, et al.: Survival differences in European patients with AIDS, 1979-89. BMJ 1994, 308:1068-1073.
68. Pedersen C, Gerstoft J, Tauris P, et al.: Trends in survival of Danish AIDS patients from 1981-1989. AIDS 1990, 4:1111-1116.
69. Friedland GH, Saltzman B, Vileno J, Freeman K, Schrager LK, Klein RS: Survival differences in patients with AIDS. J Acquir Immune Defic Syndr 1991, 4:144-153.
70. Eskild A, Magnus P, Sohlberg C, et al.: Slow progression to AIDS in intravenous drug users infected with HIV in Norway. J Epidemiol Community Health 1994, 48:383-387.